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	ABSTRACT 
SMOOTH MUSCLE CELL ORGANIZATION IN THE STEM REGION OF THE 
GRACILIS COLLATERAL CIRCULATION IN BALB/C MICE 
Laura Burckhardt 
Of the approximately 8 million Americans who suffer from ischemic peripheral arterial 
occlusive disease (PAOD), many present with intermittent claudication, or pain associated 
with exercise. Impaired vasodilation of resistance vessels is a potential explanation for this 
symptom. Occluded arteries can lead to increased flow through collateral vessels, which 
function as natural bypasses around the obstruction. This increase in blood flow and resulting 
shear stress can cause outward remodeling, or arteriogenesis, which improves the efficacy of 
collaterals. However, following femoral artery ligation in a mouse model of chronic 
ischemia, vasodilation in the stem region of collateral vessels is impaired at day 7. In the 
outwardly remodeled collateral stem, the vessel diameter increase is not associated with cell 
proliferation, suggesting the functionality of the present smooth muscle cells (SMCs) may 
account for the impaired vasodilation. A potential mechanism for increased vessel diameter 
in the collateral stem is mechanoadaptation of the vascular SMCs to adapt to the increased 
fluid shear stress as a result of the increased blood flow. Indeed, decreased SMC overlap and 
increased SMC length (indicators of mechanoadaptation) coincides with impaired 
vasodilation in the C57BL/6 mouse strain, which exhibits a large number of collateral vessels 
and robust collateral remodeling. Collateral density, remodeling following an ischemic event, 
and VEGF-A expression differ widely among mouse strains, with BALB/c mice exhibiting 
impaired arteriogenesis due to a polymorphism of the Vegfa gene. It is hypothesized that 
following femoral artery occlusion in BALB/c mice, the SMC mechanoadaptation in the 
profunda femoris artery will be impaired, which should normalize vasodilation, if 
mechanoadaptation is a cause of impaired vasodilation in the collateral stem. To test this 
hypothesis, the femoral artery was ligated in BALB/c mice, before maximal vasodilation at 
day-7 post-surgery. The animals were then perfusion fixed before resecting and 
immunostaining the profunda femoris artery to measure SMC length and overlap. The resting 
and diameters were not different at 40 ± 3 𝜇m and 48 ± 2 𝜇m, and the maximally dilated 
diamters were not different at 61 ± 4 𝜇m, and 65 ± 3 𝜇m for the control and day-7 post-
ligation profunda femoris arteries, respectively. The increase in diameter for day-7 post-
ligation and control profunda femoris arteries were not different, with a percent change of 52 ± 11% and 41 ± 3%. SMC length between day-7 post-ligation and control hindlimbs was not 
different, at 351 ± 26 𝜇m verses 318 ± 57 𝜇m in the control. SMC overlap reduced in the 
day-7 post-ligation hindlimb, 18 ± 2 𝜇m versus 22± 4 𝜇m in the control.  These results 
indicate a subtle impairment in BALB/c collateral stem remodeling, and suggest that the cell 
processes involved in increasing smooth muscle cell length may impair vasodilation 
signaling. Further studies are necessary to evaluate the causal relationship between 
mechanoadaptive remodeling and impaired vasodilation.  
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INTRODUCTION 
Peripheral Arterial Occlusive Disease 
Peripheral arterial occlusive disease (PAOD) affects approximately eight million 
Americans, and has a higher incidence with increased age, high blood pressure, smoking, 
high cholesterol, and diabetes [1, 2]. Men and woman are equally affected by PAOD, but 
there is a correlation between African-American ethnicity with increased risk [2]. More 
common in the lower extremities, PAOD is characterized by the narrowing or blockage 
of vessels that carry blood throughout the body, typically caused by a buildup of fatty 
plaque in the arteries, or atherosclerosis, Figure 1 [3, 4]. This narrowing or blockage can 
lead to ischemia, or inadequate blood flow to maintain normal tissue metabolic function 
[5]. Due to this lack of blood supply, the chief symptom of PAOD is intermittent 
claudication, or pain in the affected region with physical exertion that is alleviated with 
rest [6, 7]. Patients who present with this symptom often concurrently show impaired   
	
Figure 1: Arterial Occlusive Disease Overview. Comparison of blood flow through a 
non-atherosclerotic artery verses an atherosclerotic artery [2]. 
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vasodilation, suggesting they also have a reduced ability to regulate blood flow in non-
occluded vessels [8]. Vasodilation is critical in supporting standard tissue function by 
increasing blood flow in response to metabolic needs. 	
In patients presenting with symptoms of PAOD, there are several tests utilized in 
diagnosis. The ankle-brachial index compares ankle blood pressure with arm blood 
pressure, with a low index suggesting artery blockage [9]. Ultrasound tests utilize sound 
waves to check for blocked or diseased arteries [2]. Magnetic resonance angiography and 
computed tomographic angiography utilize a contrast dye injected through an IV, in 
conjunction with a MRI or a CT scan, respectively, to visualize the vasculature and 
identify areas of concern [7]. Patients with PAOD are at a high risk for developing 
coronary artery disease and cerebrovascular disease, which are precursors to myocardial 
infarctions and strokes, respectively [2].  
Current treatments for PAOD aim to impede the progression of disease by natural, 
pharmacologic, or mechanical mechanisms. The first line of therapy is lifestyle changes, 
such as cessation of smoking, increased exercise regimens, and diet. Post-lifestyle 
changes or in conjunction with, pharmacologic agents such as aspirin or other anti-
platelet medications are prescribed to prevent the development of PAOD-associated 
complications [6]. For patients in whom these therapies are ineffective, invasive 
approaches such as balloon angioplasty with stenting (Figure 2) or surgical bypass are 
the next treatment options. Stenting may not be a permanent solution however, as vessels 
may restenose, or re-narrow around the stent due to intimal hyperplasia [10]. In addition, 
bypass surgery is a high-risk procedure, and even if successful, may need to be revisited 
	 3 
due to occlusion of the bypass vessel [11]. Due to the sub-optimal performance of current 
treatment options, alternative therapies are necessary.  
 
 
Figure 2: Blood Flow Improvement with Stenting Intervention. 
Overview of therapeutic option for PAOD, with blood flow returned to normal 
after stenting [12]. 
	
Arteriogenesis  
 Although bypasses around occlusions can be surgically created, there are natural 
bypasses that may aid in normalizing blood flow. Initiated by a hemodynamically 
relevant stenosis of a main feeding artery, blood is redirected through alternative 
collateral vessels [13]. These vessels act as natural bypasses to the stenosis, connecting a 
high pressure region to a low-pressure region, thus increasing blood velocity and 
associated fluid shear stress through the collaterals, improving prognosis due to delivery 
of oxygen to tissue [13].  A mechanism of the vascular growth, arteriogenesis is the 
remodeling of preexisting collateral arteries, induced by the increased fluid shear stress 
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and characterized by a chronically increased luminal diameter that normalizes the fluid 
shear stress [13, 14].  
The initial shear stress of the increased blood flow leads to increased monocyte 
chemoattractant protein-1 (MCP-1) expression on endothelial cells, and of surface 
receptors involved in the tethering, rolling, and migration of monocytes. Following 
extravasation, monocytes transform into macrophages and produce numerous cytokines, 
growth factors, and enzymes. These agents include matrix-metalloproteinases (MMPs), 
which degrade the extracellular matrix to allow for outward enlargement of the vessel 
wall, and tumor necrosis factor-α (TNF-α), which is an inflammatory agent that 
positively modulates arteriogenesis [15]. VEGF is also secreted, inducing endothelial cell 
proliferation [16]. There are three regions in the collateral: the stem, midzone, and 
reentry, with the preceding mechanistic explanation most accurately reflecting 
arteriogenesis in the midzone. Interestingly, arteriogenesis of the collateral stem may 
involve either SMC proliferation, as is traditionally described, or mechanoadaptation, 
which is the rearrangement of the SMCs in order to increase vessel diameter [17,18]. 
Single factor trials for the stimulation of arteriogenesis, such as the addition of Vascular 
Endothelial Growth Factor (VEGF) or fibroblast growth factor (FGF), have failed to 
show therapeutic benefits [19]. Arteriogenesis may still offer a promising therapeutic 
target, although a holistic understanding of the mechanisms involved is crucial for 
successful next-generation therapies [13]. 
Previous Work  
SMC mechanoadaptation is characterized by morphological changes in cellular 
organization and shape [18]. This modification has been investigated in rat arterioles in 
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response to prolonged exposure of norepinephrine (NE), a vasoconstrictor [18]. 
Arterioles exposed to NE for 4 hours did not return to original resting diameter upon 
removal of the NE, due to a significant increase in SMC overlap causing remodeling of 
the vascular wall and indicating SMC mechanical reorientation Figure 3 [18]. This 
phenomenon may occur due to the mechanisms involved in increasing overlap between 
cells utilizing less energy than cellular constriction. 
Figure 3: Smooth Muscle Cell Mechanoadaptation in Rat Arterioles. Increase 
in SMC overlap in rat arterioles when exposed to the vasoconstrictor norepinephrine for 
prolonged periods of time [18]. 
 
The profunda femoris artery, the collateral stem of the gracilis collateral 
circulation, has an increased resting and maximally dilated diameter on day-7 following 
creation of a chronic ischemic model via femoral ligation. This increase was associated 
with an increase in blood flow, as well as endothelial and smooth muscle-dependent 
vasodilation impairment [20]. As the collateral enlarges, there is a phenotypic change in 
SMCs from contractile to synthetic, due to the enhanced proliferative nature of the 
synthetic phenotype. With increased counts of synthetic, non-contractile cells, although 
SMC numbers increase and the corresponding vessel diameters enlarge, vessel reactivity 
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would be impaired [21]. However, there was no difference in the number of SMCs in the 
profunda of the day-7 post-ligation hindlimb verses the control hindlimb, suggesting an 
alternate factor other than cell proliferation was involved with the observed increased 
vessel diameter, such as mechanoadaptation [20]. This was supported with observation of 
an increase in SMC length in the day-7 post-ligation hindlimb of C57BL/6 models, and a 
decrease in SMC overlap [22].  
With this observation applying to C57BL/6 models, it is important to remember 
that mouse strains differ widely in collateral density and remodeling following ischemic 
events [23]. Collateral and hindpaw perfusion were lower in BALB/c than C57BL/6, 
which can be explained by lower collateral density, and BALB/c exhibited greater 
hindlimb use impairment when compared to the C57BL/6 models. A potential molecular 
explanation for this impairment is reduced TNF-∝ expression, an inflammatory cytokine 
that positively modulates arteriogenesis, which was 50% lower in BALB/c mice. 
Additionally, a cis-acting polymorphism in the Vegfa gene in BALB/c could contribute to 
reduced VEGF-A expression, a growth factor for endothelial cell proliferation, and in 
turn decreased collateral density and remodeling [23]. These explanations are more 
associated with the classic arteriogenesis seen in the midzone region, and do not 
necessarily account for the reorganization of the smooth muscles cells seen in the stem 
region. Examination of the differences associated with each strain with regards to 
mechanoadaptation has yet to be shown in literature.   
Specific Aims of Study  
 With a high prevalence of peripheral arterial occlusive disease, and sub-optimal 
performance of current treatments options, it is clear that alternative therapeutic targets 
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need to be established. This begins with a greater understanding of the mechanism of 
collateral enlargement, the process in which preexisting collateral arteries outwardly 
remodel to form conduit vessels. Following an arterial occlusion, increase in shear stress 
induces collaterals to increase in diameter and lose functionality in terms of vasodilation. 
The number of SMCs does not increase, suggesting SMC proliferation is not the cause of 
outward collateral remodeling. SMC overlap decreases, with longer SMC lengths in 
C57BL/6 murine models, suggesting mechanoadaptation of the SMCs. Collateral density, 
remodeling following an ischemic event, and VEGF-A expression differ widely among 
murine strains, with BALB/c mice showing impaired arteriogenesis potentially due to a 
cis-acting polymorphism of the Vegfa gene. With this information in mind, the aims of 
this study were to:  
1.)  Test the hypothesis that a strain of mouse that exhibits impaired mid-zone 
arteriogenesis will also exhibit impaired mechanoadaptation, by examining 
SMC length and overlap in the stem region of the gracilis collateral circulation  
2.) Test the hypothesis that mechanoadaptation impairs vasodilation, by 
observing if an inhibited degree of mechanoadaptation results in normalized 
vasodilation in response to vasodilatory agents SNP and papaverine 
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MATERIALS AND METHODS 
Animal Husbandry  
 Male BALB/c mice were used for all experimental procedures according to the 
protocols approved by the Institutional Care and Use Committee (IACUC) of California 
Polytechnic State University (Cal Poly). All mice were maintained in a temperature and 
12-hour light cycle controlled room in the University Vivarium. Mice were specifically 
housed by litter in micro-isolator cages, supplied with feed, water, and enrichment 
(houses and tubes), and monitored daily.  
Collateral Enlargement Model 
A murine collateral enlargement model was created via femoral artery ligation in 
the left hindlimb of the animals. Prior to surgery, the surgical bench was disinfected with 
70% isopropyl alcohol, and all surgical instruments and materials were sterilized in an 
autoclave. After weighing the animal, mice were anesthetized using 1-3% isoflourane gas 
at an oxygen flow rate between 0.8-1.2 l⋅min-1, administered through a nose-cone. Hair 
on the anterior hindlimb was depilated, and surgical area was disinfected with Nolvasan. 
The mice were placed in a supine position on a controlled heated surgical stage, with a 
rectal probe monitoring the animal’s core-body temperature. Veterinary ointment was 
added to the eyes to avoid corneal desiccation. 
 A small incision was made on the middle, medial aspect of the left thigh, which 
was then extended to the abdominal wall. The subcutaneous connective tissue was blunt 
dissected to maximize surgical exposure. Throughout the procedure, the incision site was 
irrigated with sterile phosphate buffered saline (PBS) to prevent tissue desiccation. To 
expose the ligation site, the epigastric fat pad was reflected medially following blunt 
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dissection. The femoral artery was blunt dissected from the neurovascular bundle 
downstream from the deep femoral branch. The femoral artery was ligated with 6.0 silk 
suture distal to the epigastric branch and proximal to the popliteal branch, Figure 4. The 
skin was closed using 7.0 polypropylene suture. For control, the surgical procedure 
outlined previously was performed on the contralateral hindlimb, with the exception of 
the ligation of the femoral artery. Post-surgery, animals were given a subcutaneous 
injection of buprenorphine (0.075mg/kg), and supplied with buprenorphine water (0.01 
mg/mL) for 2-3 days.  
 
Figure 4.  Overview of Hindlimb Vascular Flow. A) Normal blood flow through hindlimb, 
directionally indicated though dotted lines and arrows. B) Indicated site of ligation with resulting 
redirection of blood flow through the profunda femoris artery and collateral [21]. 
 
Clinical Ambulation Scoring  
 
 Following the surgery, animals were observed daily for ambulation, and scored 
from 0-3 based on hindpaw range of motion. A dragging hindpaw established a score of 
3, no plantar flexion and constant dorsiflexion constituted a score of 2, some planar 
flexion a 1, and normal use a 0. Animals were monitored until normal ambulation was 
observed on two consecutive days, or until day-7 post-ligation. 
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Intravital Microscopy  
 
 To analyze the vasodilatory capacity of the collateral stem, vasodilation was 
assessed in mice 7-days post-ligation. The surgical area was prepared and mice were 
anesthetized as described previously. A small incision was made on the middle, medial 
aspect of the left hindlimb, with the incision continued up the abdominal wall. The 
subcutaneous connective tissue was blunt dissected to maximize surgical exposure, the 
epigastric artery vein pair was cauterized and the epigastric fat pad was removed. The 
skin overlying the saphenous artery-vein pair and profunda femoris artery-vein pair was 
removed to maximize exposure and improve visibility. PBS was dripped over exposed 
tissue, and plastic wrap was placed over area to prevent desiccation, before a 30–minute 
equilibration period before vasodilator application, during which time the contralateral 
limb was exposed.  
 An intravital microscope, the Olympus BXFM, with a 5x objective and interface 
with QCapture imaging software was utilized to capture images of the profunda femoris 
artery at rest and following maximal vasodilation. This dilation was in response to 
sodium nitroprusside (SNP, 10-3) and papaverine (10-2), which were applied for 5 minutes 
prior to imaging. This procedure was repeated on the contralateral side.  
Sample Perfusion and Fixation  
 In order to ensure cylindrical vascular dimensions were preserved post-resection, 
mice were perfusion fixed. Through a thoracotomy, an incision was made in the apex in 
the heart into the left ventricle, and a catheter was inserted and secured with a vascular 
clamp. A cycle of 10mL PBS, then 5mL 4% paraformaldehyde (PFA), followed by 10ml 
PBS was driven through the catheter, with a syringe pump (4 mL/min). During this cycle, 
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SNP and papaverine were applied to the superficial areas of the hindlimb, to ensure that 
the maximum diameter of the profunda femoris was maintained. Post fixation, the 
anterior gracilis muscle and profunda femoris artery were resected and post-fixed in 4% 
PFA for approximately 24 hours before being rinsing and storing in PBS at 4°C.  
Confocal Microscopy 
 
Confocal microscopy was used to visualize smooth muscle cells around each 
artery. Samples were stained with 1:200 1A4 clone (α-smooth muscle actin, Cy3 
conjugate) with 0.1% saponin and 2% BSA reconstituted in PBS for 7 days, with 0.3 mL 
of solution per sample. Following, they were washed in 0.1% saponin in PBS 3x for 20 
minutes at room temperature, and then in PBS for 30 minutes. The samples were then 
mounted onto depression slides with 50/50 PBS and Glycerol. Utilizing a confocal 
microscope and 40x oil immersion objective, images of the profunda femoris artery were 
captured with Fluoview Viewer (FV10-ASW 4.1) software. Image stacks in the z 
direction were taken with 1-micron slices to approximately half the diameter for each 
artery.  
Image Analysis  
 The intravital microscopy images of the profunda femoris at rest and maximum 
dilation were used to measure average diameter of the vessel at those two conditions. The 
z-stacks of the profunda femoris, taken with the confocal microscope, were merged into 
single, 3-D reconstructions. These images were used to measure average smooth muscle 
cell overlap between the individual cells, determined by measuring all of the 
distinguishable overlaps between cells on the image, and averaging those values. In 
addition, smooth muscle cell length measurements were determined based on a formula 
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validated in previous studies [18, 24], utilizing statistical patterns of SMC orientation to 
establish average SMC lengths with a single view of the image. This formula requires 
several assumptions, as follows:  
1. The vessels studied are fully dilated and cylindrical in shape.  
2. There is only one layer of SMCs surrounding the studied vessel.  
3. The SMCs have 2 end points only.  
4.  There are only two visible types of cells: “wrap cells, extending across the 
entire visible portion of the vessel, and “taper” cells, partially extending 
the visible portion of the vessel.  
 A 100µm length of artery was delineated for each 3D reconstruction, and average 
SMC length for each vessel, Lv, was determined using Equation 1 below [18, 24]:  𝐿! = 4𝜋𝑅!𝐹(𝑆! + 𝑆!)/𝑇!                                               (Eq. 1) 
In equation 1, Lc is the average SMC length, Rv is the radius of the artery, F is the 
fraction of vessel circumference in which measurements were made, Sw is the number of 
wrap cells, St is the length of all tapered cells divided by the length of one wrap cell, and 
Tv is the number of taper cells.  
Statistical Analysis   
Independent Student’s t-tests were performed between the data from control and 
day-7 post-ligation hindlimbs, as well as the ambulation data between mice strains. A p-
value of less than 0.05 indicated statistical significance.  
 
 
 
 
 
 
	 13 
RESULTS 
 
 The aims of this study were to test the hypothesis of smooth muscle cell 
mechanoadaptation impairment in BALB/c mice during outward remodeling of the 
collateral stem following an ischemic event, as well as examine if impaired 
mechanoadaptation normalized vasodilation. The first objective within these aims was to 
investigate functional hindlimb use impairment when compared to C57BL/6 mice, which 
possess well-developed collaterals, as quantified by clinical ambulation scoring. The 
second objective was to measure the resting and maximally-dilated profunda femoris 
artery in vivo to test if collateral enlargement occurred, along with impaired vasodilation 
7 days post-ischemic event. The third objective was to test the hypothesis of 
mechanoadaptation by determining SMC overlap and length in the profunda.  
Clinical Ambulation Scoring  
 
It was expected that BALB/c mice would have greater functional hindlimb 
impairment when compared to C57BL/6 mice [22]. The recovery time to normal 
hindlimb ambulation trended towards longer in BALB/c mice, with 6 ± 0.4 days, where 
C57BL/6 mice required 5 ± 0.3 days, Figure 5.   
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Figure 5: Murine Strain Comparison of Days to Normal Ambulation. Average days 
to return to normal hindlimb use following ischemic event, as determined by clinical 
ambulation scoring. 
 
Functional Vasodilation in the Ischemic Profunda  
 
 As poor ambulation results are suggestive of functional impairment, this was next 
examined. Both resting and maximally dilated diameters of the profunda femoris artery 
on the day-7 post-ligation limbs trended towards greater diameters than the control 
hindlimb, although the results were not statistically significant (p > 0.05). The resting 
diameters were 40 ± 3 𝜇m and 48 ± 2 𝜇m, and the maximally dilated diameters were 61 ± 4 𝜇m 65 ± 3 𝜇m for the control and day-7 post-ligation hindlimbs, respectively. The 
increase in diameter for day-7 post-ligation and control limbs were not different, and 
represented a percent change of 52 ± 11% and 41 ± 3%, respectively (Figure 6). 
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Figure 6: Functional Vasodilation in Ischemic Profunda. A) Representative images of 
profunda femoris at resting diameter and B) at maximally dilated diameter in response to 
papaverine and SNP C) Average vessel diameter resting and maximally dilated diameters for 
control and day-7 post-ligation hindlimbs. D) Percent change in vessel diameter from resting 
to maximum dilation, n=7. 
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Mechanoadaptation 
 The absence of impaired vasodilation is suggestive of a lack of remodeling, so 
indicators of mechanoadaptation, SMC length and overlap, were examined. The smooth 
muscle cells trended towards longer lengths in the day-7 post-ligation hindlimb compared 
to the control hindlimb, although the results were not significant (p>0.05), with the 
lengths in the control hindlimb of 318 ± 57 𝜇m, and in the day-7 post-ligation hindlimb 
of 351 ± 26 𝜇m. An overview of the types of SMCs, wrap and taper, which were used to 
calculate SMC lengths can be seen in Figure 7, with the results in Figure 8.   
 
Figure 7: Confocal Microscopy View of Profunda Femoris Smooth Muscle Cells. 1) 
Taper cell partially extends across visible artery portion. 2) Wrap cell extends across 
entire visible portion of artery 
 
 
1 
2 
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Figure 8: Profunda Femoris Artery Smooth Muscle Cell Length. Average SMC 
lengths in profunda femoris artery of control and day-7 post-ligation hindlimbs, n=5 
control, n=6 day-7.  
 
The average SMC overlap in the control hindlimb was longer than the SMC overlap in 
the day-7 post-ligation hindlimb, at 22 ± 4 𝜇m in the control hindlimb and 18 ± 2 𝜇m in 
the day-7 post-ligation hindlimb, p<0.05.  
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Figure 9: Profunda Femoris Artery Smooth Muscle Cell Overlap. A) Example of 
overlap between two SMCs using confocal microscopy at 40x. B) Average SMC overlap 
in the profunda femoris artery in the control and day-7 post-ligation hindlimbs, n=5 
control, n=6 day-7; p<0.05. 
 
 
 
 
 
B 
    Control                                     Day-7 
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DISCUSSION  
 
 Patients who suffer from peripheral arterial occlusive disease may experience 
intermittent claudication, which may be explained by impaired vasodilation. Therefore, 
restoring normal vasodilation may reduce associated symptoms, and improve patient 
prognosis. In mouse models with robust collateral networks and collateral growth, 
impaired vasodilation can be explained by smooth muscle cell dysfunction, presumably 
as a result of mechanoadaptation (increased SMC length and decreased SMC overlap) in 
the context of collateral enlargement. Therefore, we sought to support the causal role of 
mechanoadaptation in impaired vasodilation by evaluating the degree of 
mechanoadaptation in an animal model that exhibits reduced arteriogenesis, and the 
associated vasodilation.  
 The first objective of the study was to test the hypothesis that an animal model 
that exhibits reduced arteriogenesis results in decreased functional use following an 
ischemic event, by examining functional hindlimb use post-femoral artery ligation in 
comparison to the C57BL/6. This examination allows for calibration of the work to other 
relative investigative groups, as ambulation scoring is a common assessment. The 
average amount of days to normal ambulation trended towards higher in BALB/c 
compared to C57BL/6. This trend was consistent with previous studies, but significance 
was not observed. As BALB/c exhibit fewer pre-existing collaterals and decreased 
collateral remodeling, the lack of significance may be due to subjectivity of ambulation 
scoring, and the resulting inconsistency between the score assigners.  
 As ambulation scoring only assesses overall functional use of the hindlimb, the 
second more specific aim of the study investigated functional vasodilation in the ischemic 
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profunda. Both resting and maximally dilated average diameters of the profunda femoris 
trended towards greater than the control hindlimb, suggesting arteriogenesis characterized 
by outward remodeling had ensued, although the results were not significant. The percent 
change in diameter from resting to maximum dilation was not different in the control and 
day-7 post-ligation hindlimbs, suggesting vasodilation was not impaired. If 
mechanoadaptation is impaired within BALB/c mice, this finding is consistent with the 
hypothesis that mechanoadaption impairs vasodilation.  
 With normal vasodilation observed in the samples, the final aim of the study was 
to examine the presence and degree of mechanoadaptation in the ischemic hindlimb, 
characterized by a decrease in SMC overlap and an increased length. There was not an 
increase in SMC length in the day-7 post-ligation hindlimb compared to the control 
hindlimb, but there was a decrease in SMC overlap. This suggests a subtle form of 
mechanoadaptation in the SMCs of the collateral stem of the ischemic profunda, but an 
impairment in the degree of remodeling as compared to the C57BL/6 model, potentially 
due to lower amounts of TNF-∝ and VEGF-A comparatively seen in this strain [23]. It 
would be interesting to examine whether the presence of these two factors would enhance 
SMC mechanoadaptation in the BALB/c, which could offer further clarity into a potential 
therapeutic target. To establish a necessary and sufficient relationship, TNF-∝ and 
VEGF-A could be inhibited in separate  experiments, and the degree of 
mechanoadaptation in the stem region of the profunda femoris observed.  
 There were several limitations in this study that may have contributed to 
variability in the results. In the formula for SMC length, several assumptions were made. 
One assumption was that the vessels were fully dilated and cylindrical in shape, which is 
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not entirely feasible even with the precautions of perfusion fixation and the utilization of 
a depression slide for imaging. Furthermore, it was assumed that there is only one layer 
of SMCs on the vessel, which was not verified. In the comparison of results from the 
BALB/c to the C57BL/6 models, the data was compared from two different surgeons. 
Differences in technique may have led to variation in the data in which a comparison was 
not appropriate.  
 Overall, there is a promising correlation between impaired vasodilation and 
mechanoadaption in varying murine strains. The effect of factors that differ in mice 
strains such as VEGF-A expression, TNF-∝ levels, and pre-existing collaterals on 
impaired mechanoadaptation need to be established. With further study, the potential 
correlation between mechanoadaptation and impaired vasodilation can be prospectively 
utilized to establish a causal relationship to help better understand impaired vasodilation 
and other factors involving peripheral arterial occlusive disease. A better understanding 
of these relationships will hopefully lead to establishing an effective target for future 
therapeutics.   
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APPENDIX A: Femoral Artery Ligation Protocol  
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APPENDIX B: Perfusion Fixation Protocol   
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APPENDIX C: ASMA Staining Protocol  
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APPENDIX D: Confocal Protocol      
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APPENDIX E: Raw Images  
 
In vivo imaging (5x) 
 
N=1 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated  
 
N=1 Profunda Femoris Artery Control A) Resting B) Maximally Dilated 
 
N=2 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated 
 
N=2 Profunda Femoris Artery Control A) Resting B) Maximally Dilated 
A      B 
A      B 
A       B 
A                                       B 
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N=3 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated
 
N=3 Profunda Femoris Artery Control A) Resting B) Maximally Dilated 
 
N=4 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated 
 
 
N=4 Profunda Femoris Artery Control A) Resting B) Maximally Dilated 
A                       B 
A      B 
A                    B 
A                         B 
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N=5 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated 
 
 
N=5 Profunda Femoris Artery Control A) Resting B) Maximally Dilated 
 
 
 
N=6 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated 
A                         B 
A                                  B 
A                         B 
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N=6 Profunda Femoris Artery Control A) Resting B) Maximally Dilated  
 
 
N=7 Profunda Femoris Artery Day-7 Post-Ligation A) Resting B) Maximally Dilated 
 
 
N=7 Profunda Femoris Artery Control A) Resting B) Maximally Dilated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A                                 B 
A                             B 
A                                   B 
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Confocal Images (40x) 
 
 
N=1 Profunda Femoris Artery Day-7 
 
N=1 Profunda Femoris Artery Control 
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N=2 Profunda Femoris Artery Day-7 
 
N=3 Profunda Femoris Artery Day-7 
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N=3 Profunda Femoris Artery Control 
 
N=4 Profunda Femoris Artery Day-7 
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N=4 Profunda Femoris Artery Control 
 
N=5 Profunda Femoris Artery Day-7 
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N=5 Profunda Femoris Artery Control 
 
N=6 Profunda Femoris Artery Day-7 
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N=6 Profunda Femoris Artery Control 
 
N=7 Profunda Femoris Artery Day-7 
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N=7 Profunda Femoris Artery Control 
 
N=8 Profunda Femoris Artery Day-7 
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N=8 Profunda Femoris Artery Control 
 
